Lindus Health Named Fierce CRO Award Winner in the Outstanding Patient Recruitment and Retention Category
Lindus Health earned this recognition for its innovative use of the Patient Identification Center (PIC) technique, which leverages advanced algorithms and customized search protocols based on real-world medical record data to reduce screen fail rates and accelerate recruitment with greater precision. This approach was instrumental in its collaboration with Myota on a pre-diabetes trial, which achieved a 54% screening conversion rate—five times the industry benchmark—and completed enrollment in just four months.
Backed by deep expertise in healthcare data, clinical systems, and physician behavior, Lindus Health's unique PIC approach stands out not just for using EHR-driven participant searches, but for how it executes them. While many CROs rely on medical practices to run standard queries, Lindus builds its own highly customized, in-house searches. These go beyond basic inclusion and exclusion criteria, incorporating a nuanced understanding of how data is actually recorded and coded by general practitioners. For example, when a trial sought patients with "reduced sexual desire," Lindus optimized results by using "low libido"—a term more commonly coded by GPs—significantly improving the ability to identify eligible participants.
"Receiving the Fierce CRO Award is a tremendous honor," said Meri Beckwith, co-founder of Lindus Health. "It reflects our mission to fix the broken clinical trial model so patients can access treatments faster. With innovative strategies like our PIC technique, smart study design, and proprietary AI, we're delivering faster, more precise, and cost-effective trials—even in complex cases. Our work isn't done though, and we're continuing to push the boundaries of what's possible in clinical research, making it more efficient, inclusive, and patient-centric every step of the way."
This award comes on the heels of Lindus Health's Series B funding round of $55 million, which is fueling strategic hiring across clinical operations and product development, while expanding the capabilities of its proprietary AI-powered eClinical platform, Citrus™. The investment is enabling advancements in study design optimization, automated central monitoring, and real-time biostatistics. As the only major service provider with a fully in-house platform, Lindus integrates all core clinical research technologies—including CTMS, EDC, eDiary, visit scheduling, and more—into a seamless, unified ecosystem.
In partnership with Oxford University, Lindus Health published a study on diverse perceptions of clinical trial participation, helping to inform more inclusive and patient-centered research. Additionally, Lindus is collaborating with CDISC, the organization that sets clinical data standards for the FDA, to develop standardized templates for clinical observations and is contributing to ARIA's Safeguarded AI program to improve trial design through safer, more reliable AI.
The full Fierce CRO Awards report profiling all winners is available here. Lindus Health's award-winning capabilities can be found at www.lindushealth.com.
About Lindus Health
Lindus Health is an anti-CRO running radically faster, more reliable clinical trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. This is achieved through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 40 million Electronic Health Records.
Clinical trials are the biggest bottleneck to advances in healthcare. Lindus Health removes this constraint through end-to-end execution of clinical studies driven by technology and forward-thinking approaches to clinical operations.
To date, Lindus Health has delivered clinical trials across the US, UK, and Europe to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $80M from investors including Peter Thiel, Balderton, Creandum, Firstminute Capital, and Seedcamp.
About Fierce BiotechFierce Biotech is the biotech industry's daily monitor, providing the latest news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day's top stories. Signup is free here.
Press contact:
Jodi PerkinsAmendola Communications for Lindus HealthJperkins@acmarketingpr.com Cell: 847.508.0877
View original content to download multimedia:https://www.prnewswire.com/news-releases/lindus-health-named-fierce-cro-award-winner-in-the-outstanding-patient-recruitment-and-retention-category-302485421.html
SOURCE Lindus Health
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Earnings Preview: What To Expect From Rockwell Automation's Report
Milwaukee, Wisconsin-based Rockwell Automation, Inc. (ROK) provides industrial automation and digital transformation solutions in the Americas, EMEA, and the Indo-Pacific. With a market cap of $39.1 billion, Rockwell operates through Intelligent Devices, Software & Control, and Lifecycle Services segments. The company is expected to release its Q3 results on Wednesday, Aug. 6. Ahead of the event, analysts expect ROK to report a profit of $2.68 per share, down 1.1% from $2.71 per share reported in the year-ago quarter. On the positive note, the company has surpassed the Street's bottom-line estimates in each of the past four quarters. More News from Barchart Dear Google Stock Fans, Mark Your Calendars for July 23 Retirement Ready: 3 Dividend Stocks to Set and Forget Dear UnitedHealth Stock Fans, Mark Your Calendars for July 29 Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For the full fiscal 2025, analysts expect ROK to report an EPS of $9.77, marginally up from $9.71 in fiscal 2024. In fiscal 2026, its earnings are expected to soar 16.1% year-over-year to $11.34 per share. ROK stock has surged 19.5% over the past 52 weeks, outperforming the Industrial Select Sector SPDR Fund's (XLI) 17.3% gains and the S&P 500 Index's ($SPX) 10.5% returns during the same time frame. Rockwell Automation's stock prices soared 11.9% following the release of its better-than-expected Q2 results on May 7. Due to a drop in organic revenues and currency headwinds, the company's sales for the quarter declined 5.9% year-over-year to $2 billion, but surpassed the consensus estimates by 1.5%. Its adjusted EPS for the quarter also declined 2% year-over-year to $2.45, but surpassed the Street expectations by 17.2%. Meanwhile, the company improved its full-year topline guidance and raised its full-year EPS guidance from the previously announced range of $8.60- $9.80 to $9.20 - $10.20, boosting investor confidence. The stock has a consensus 'Moderate Buy' rating overall. Of the 23 analysts covering the stock, opinions include 11 'Strong Buys,' 11 'Holds,' and one 'Strong Sell.' As of writing, the stock is trading notably above its mean price target of $330.38. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Palantir Shares Climb After 'Stunning' Growth Sparks Mizuho Upgrade
July 16 - Palantir (NASDAQ:PLTR) shares climbed about 1% on Wednesday after Mizuho Securities elevated its rating to Neutral from Underperform, citing stunning revenue momentum. Mizuho analyst Gregg Moskowitz highlighted that Palantir's commercial and government segments have consistently outpaced expectations, with material upward revisions across both lines. He noted the company could extend its revenue growth streak to a fifth straight quarter when it reports Q2 results in early August. Palantir is set to release fiscal Q2 2025 figures on Aug. 4. The consensus estimate calls for adjusted EPS of $0.14 on revenue of $939.3 million. In Q1, Palantir delivered 39% year?over?year revenue growth, building on gains of 21%, 27%, 30% and 36% in the four quarters of fiscal 2024. Analysts expect Q2 growth to remain near 3940% year?over?year. Moskowitz warned that Palantir's valuation multiple sits well above peers in software, suggesting a risk of multiple reversion in coming quarters. Still, he argued the company's unique positioning in AI, government digital transformation and industrial modernisation justifies a degree of premium. Investors will watch whether Palantir can meet lofty expectations in August, which may influence its longer?term outlook. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
TSMC Raises 2025 Outlook in Big Boost for AI Demand Hopes
(Bloomberg) -- Taiwan Semiconductor Manufacturing Co. raised its outlook for 2025 revenue growth, shoring up investors' confidence in the momentum of the global AI spending spree. The Dutch Intersection Is Coming to Save Your Life Advocates Fear US Agents Are Using 'Wellness Checks' on Children as a Prelude to Arrests LA Homelessness Drops for Second Year Manhattan, Chicago Murder Rates Drop in 2025, Officials Say The world's biggest contract chipmaker on Thursday forecast sales growth of about 30% in US dollar terms this year, up from mid-20% previously. That reinforced expectations that tech firms from Meta Platforms Inc. to Google will keep spending to build the datacenters essential to artificial intelligence development. Nasdaq stock index futures swung to gains. TSMC's move underscores resilient demand for high-end chips from the likes of Nvidia Corp. and Advanced Micro Devices Inc., which is outpacing its production capacity. Chief Executive Officer C.C. Wei affirmed during a shareholder meeting in June that AI orders continue to run hot — seeking to dispel persistent speculation that tech firms may curtail spending. This is 'supporting the AI value chain, and AI optimism still holds,' said Billy Leung, investment strategist at Global X ETFs in Sydney. 'For investors, TSMC results again ease fears of an AI slowdown. Margins hold, demand outlook good, generally reinforces the AI buildout is still well underway.' Investors have piled back into AI-linked companies, shaking off a funk that settled in after China's DeepSeek cast doubt on whether the likes of Inc. needed to spend that much money on data centers. Last week, Nvidia became the first company in history to hit a $4 trillion valuation, underscoring investors' renewed enthusiasm for companies like TSMC that are key to building the infrastructure for AI. TSMC wasn't hiking its outlook on news the US is prepared to grant Nvidia licenses to export its H20 AI chip to China, Wei told reporters. While that resumption in sales was positive for the industry, it was too early to quantify the impact, he added. A day before TSMC's results, chipmaking gear supplier ASML Holding NV triggered anxiety across markets by walking back its own growth forecast for 2026. Geopolitics and the global economy are sources of 'increasing uncertainty,' Chief Executive Officer Christophe Fouquet said. Its shares dropped more than 11%. Wei on Thursday acknowledged the uncertainty stemming from the Trump administration's tariffs-led assault. The appreciating Taiwanese dollar is also suppressing its financials. 'Looking ahead to the second half of the year, we have not seen any change in our customers' behavior so far,' he said in Taipei. 'However, we understand there are uncertainties and risks' related to potential tariffs. TSMC upgraded its forecast after reporting a better-than-expected 61% jump in net income for the June quarter to NT$398.3 billion ($13.5 billion), keeping intact a streak of beating estimates every quarter since 2021. The company previously posted a 39% surge in revenue. Revenue from high-performance computing — which includes chips for servers and datacenters — now accounts for three-fifths of the company's revenue, a major change from when TSMC primarily rode the smartphone market. It remains the main chipmaker to Apple Inc. The company is sticking with plans to spend $38 billion to $42 billion upgrading and expanding capacity this year. TSMC had earlier pledged to spend another $100 billion ramping up manufacturing in Arizona, Japan, Germany and back home in Taiwan. --With assistance from Dasha Afanasieva, Gao Yuan, Winnie Hsu, Vlad Savov and Cindy Wang. (Updates with market action, commentary from the second paragraph.) How Starbucks' CEO Plans to Tame the Rush-Hour Free-for-All Forget DOGE. Musk Is Suddenly All In on AI How Hims Became the King of Knockoff Weight-Loss Drugs The Quest for a Hangover-Free Buzz Thailand's Changing Cannabis Rules Leave Farmers in a Tough Spot ©2025 Bloomberg L.P. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
